Find information on thousands of medical conditions and prescription drugs.

Alcoholic hepatitis

Hepatitis is a gastroenterological disease, featuring inflammation of the liver. The clinical signs and prognosis, as well as the therapy, depend on the cause. more...

Home
Diseases
A
Aagenaes syndrome
Aarskog Ose Pande syndrome
Aarskog syndrome
Aase Smith syndrome
Aase syndrome
ABCD syndrome
Abdallat Davis Farrage...
Abdominal aortic aneurysm
Abdominal cystic...
Abdominal defects
Ablutophobia
Absence of Gluteal muscle
Acalvaria
Acanthocheilonemiasis
Acanthocytosis
Acarophobia
Acatalasemia
Accessory pancreas
Achalasia
Achard syndrome
Achard-Thiers syndrome
Acheiropodia
Achondrogenesis
Achondrogenesis type 1A
Achondrogenesis type 1B
Achondroplasia
Achondroplastic dwarfism
Achromatopsia
Acid maltase deficiency
Ackerman syndrome
Acne
Acne rosacea
Acoustic neuroma
Acquired ichthyosis
Acquired syphilis
Acrofacial dysostosis,...
Acromegaly
Acrophobia
Acrospiroma
Actinomycosis
Activated protein C...
Acute febrile...
Acute intermittent porphyria
Acute lymphoblastic leukemia
Acute lymphocytic leukemia
Acute mountain sickness
Acute myelocytic leukemia
Acute myelogenous leukemia
Acute necrotizing...
Acute promyelocytic leukemia
Acute renal failure
Acute respiratory...
Acute tubular necrosis
Adams Nance syndrome
Adams-Oliver syndrome
Addison's disease
Adducted thumb syndrome...
Adenoid cystic carcinoma
Adenoma
Adenomyosis
Adenosine deaminase...
Adenosine monophosphate...
Adie syndrome
Adrenal incidentaloma
Adrenal insufficiency
Adrenocortical carcinoma
Adrenogenital syndrome
Adrenoleukodystrophy
Aerophobia
Agoraphobia
Agrizoophobia
Agyrophobia
Aicardi syndrome
Aichmophobia
AIDS
AIDS Dementia Complex
Ainhum
Albinism
Albright's hereditary...
Albuminurophobia
Alcaptonuria
Alcohol fetopathy
Alcoholic hepatitis
Alcoholic liver cirrhosis
Alektorophobia
Alexander disease
Alien hand syndrome
Alkaptonuria
Alliumphobia
Alopecia
Alopecia areata
Alopecia totalis
Alopecia universalis
Alpers disease
Alpha 1-antitrypsin...
Alpha-mannosidosis
Alport syndrome
Alternating hemiplegia
Alzheimer's disease
Amaurosis
Amblyopia
Ambras syndrome
Amelogenesis imperfecta
Amenorrhea
American trypanosomiasis
Amoebiasis
Amyloidosis
Amyotrophic lateral...
Anaphylaxis
Androgen insensitivity...
Anemia
Anemia, Diamond-Blackfan
Anemia, Pernicious
Anemia, Sideroblastic
Anemophobia
Anencephaly
Aneurysm
Aneurysm
Aneurysm of sinus of...
Angelman syndrome
Anguillulosis
Aniridia
Anisakiasis
Ankylosing spondylitis
Ankylostomiasis
Annular pancreas
Anorchidism
Anorexia nervosa
Anosmia
Anotia
Anthophobia
Anthrax disease
Antiphospholipid syndrome
Antisocial personality...
Antithrombin deficiency,...
Anton's syndrome
Aortic aneurysm
Aortic coarctation
Aortic dissection
Aortic valve stenosis
Apert syndrome
Aphthous stomatitis
Apiphobia
Aplastic anemia
Appendicitis
Apraxia
Arachnoiditis
Argininosuccinate...
Argininosuccinic aciduria
Argyria
Arnold-Chiari malformation
Arrhythmogenic right...
Arteriovenous malformation
Arteritis
Arthritis
Arthritis, Juvenile
Arthrogryposis
Arthrogryposis multiplex...
Asbestosis
Ascariasis
Aseptic meningitis
Asherman's syndrome
Aspartylglycosaminuria
Aspergillosis
Asphyxia neonatorum
Asthenia
Asthenia
Asthenophobia
Asthma
Astrocytoma
Ataxia telangiectasia
Atelectasis
Atelosteogenesis, type II
Atherosclerosis
Athetosis
Atopic Dermatitis
Atrial septal defect
Atrioventricular septal...
Atrophy
Attention Deficit...
Autoimmune hepatitis
Autoimmune...
Automysophobia
Autonomic dysfunction
Familial Alzheimer disease
Senescence
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

Signs and symptoms

Hepatitis is characterised by fatigue, malaise, joint aches, abdominal pain, vomiting 2-3 times per day for the first 5 days, loss of appetite, dark urine, fever, hepatomegaly (enlarged liver) and jaundice (icterus). Some chronic forms of hepatitis show very few of these signs and only present when the longstanding inflammation has led to the replacement of liver cells by connective tissue; the result is cirrhosis. Certain liver function tests can also indicate hepatitis.

Types of hepatitis

Viral

Most cases of acute hepatitis are due to viral infections:

  • Hepatitis A
  • Hepatitis B
  • Hepatitis C
  • D-agent (requires presence of the hepatitis B virus)
  • Hepatitis E
  • Hepatitis F (discredited)
  • Hepatitis G
Please see the respective articles for more detailed information.
See also infectious canine hepatitis.

Hepatitis A

Hepatitis A is an enterovirus transmitted by the orofecal route, such as contaminated food. It causes an acute form of hepatitis and does not have a chronic stage. The patient's immune system makes antibodies against hepatitis A that confer immunity against future infection. People with hepatitis A are usually advised to rest, stay hydrated and avoid alcohol. A vaccine is available that will prevent infection from hepatitis A for life. It can be spread through personal contact,consumption of raw sea food or drinking contaminated water.

Hepatitis B

Hepatitis B causes both acute and chronic hepatitis in some patients who are unable to eliminate the virus. Identified methods of transmission include blood (blood transfusion, now rare), tattoos (both amateur and professionally done), horizontally (sexually or through contact with blood or bodily fluids), or vertically (from mother to her unborn child). However, in about half of cases the source of infection cannot be determined. Blood contact can occur by sharing syringes in intravenous drug use, shaving accessories such as razor blades, or touching wounds on infected persons. Needle-exchange programmes have been created in many countries as a form of prevention. In the United States, 95% of patients clear their infection and develop antibodies against hepatitis B virus. 5% of patients do not clear the infection and develop chronic infection; only these people are at risk of long term complications of hepatitis B.

Patients with chronic hepatitis B have antibodies against hepatitis B, but these antibodies are not enough to clear the infection that establishes itself in the DNA of the affected liver cells. The continued production of virus combined with antibodies is a likely cause of immune complex disease seen in these patients. A vaccine is available that will prevent infection from hepatitis B for life. Hepatitis B infections result in 500,000 to 1,200,000 deaths per year worldwide due to the complications of chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Hepatitis B is endemic in a number of (mainly South-East Asian) countries, making cirrhosis and hepatocellular carcinoma big killers. There are three, FDA-approved treatment options available for persons with a chronic hepatitis B infection: alpha-interferon, adefovir and lamivudine. In about 45% of persons on treatment achieve a sustained response.

Read more at Wikipedia.org


[List your site here Free!]


Presence of TT virus infection in chronic hepatitis patients from a hospital in New Delhi, India
From Indian Journal of Medical Research, 7/1/05 by Chattopadhyay, Saket

Background & objectives: The recent discovery of a novel parenterally transmitted, unenveloped, single-stranded DNA virus called TT virus (TTV) in chronic hepatitis patients with unclear pathogenesis throughout the world led us to investigate, its presence in chronic hepatitis patients attending a hospital in New Delhi, India, and to evaluate its role in liver disease.

Methods: TT virus DNA was investigated in serum samples of 70 patients with various types of chronic hepatitis, and 100 healthy subjects from New Delhi, India by nested PCR using the primers that belonged to UTR (A) region of the genome.

Results: TTV DNA was detected in 6 of 23 patients (26%) with type B chronic hepatitis, 3 of 20 patients (15%) with type C chronic hepatitis, and 12 of 100 subjects (12%) from healthy control group with normal liver function profile tests. None of the 27 non-B, non-C chronic hepatitis patients had TTV DNA positivity. The prevalence of TTV was significantly higher in type-B chronic hepatitis patients as compared to normal subjects (P

Interpretation & conclusions: Interestingly, in chronic hepatitis patients, TTV was always associated with either hepatitis B or C virus indicating a likely parenteral route of transmission. All TTV-positive subjects in healthy control group showed normal clinical and biochemical profiles. Thus, the presence of TTV infection is unlikely to influence the course of chronic hepatitis related to hepatitis B virus (HBV) or hepatitis C virus (HCV) or cause liver diseases in healthy subjects.

Key words Polymerase chain reaction - TT virus - type-B hepatitis - type-C hepatitis

Throughout the world there still remain patients with chronic liver diseases unexplained by hepatitis C or B viruses (HCV or HBV)1-6. The discovery of hepatitis G (HG) virus failed to show that this virus was the major cause of non-B, non-C chronic hepatitis7. Recent discovery of TT virus (TTV), a non enveloped single-stranded circular DNA virus from Japan has rekindled the hope of a hepatotrophic virus that may be able to explain the non-B, non-C chronic hepatitis cases2,5. TTV is a negative-stranded circular DNA virus measuring 30-50 nm that belongs to the Circoviridae8. Prevalence of TTV in chronic hepatitis patients and voluntary blood donors in western India was found to be 6.7 and 7.4 per cent respectively1, but TTV was not found to be an important cause of chronic liver diseases. Information regarding the prevalence and clinical significance of TTV in viral hepatitis patients from northern India is scanty. We investigated the presence of TTV DNA in serum samples of patients with chronic hepatitis attending a hospital in New Delhi, India and healthy subjects, and the possible role of TTV in non-B, non-C chronic hepatitis was also evaluated.

Material & Methods

Patients: A total of 70 consecutive patients with biopsy proven chronic hepatitis, who visited the Out Patient Clinic of Lok Nayak Jai Prakash Hospital, New Delhi between July 2001 and June 2002, were included in the study. Serum samples were taken as baseline followed by samples taken at 1-3 months intervals. Patients were diagnosed as having chronic hepatitis, using conventional clinical, biochemical and histological criteria9. The mean duration of the disease was 13 ± 4 months. Anti-HCV or HBsAg positive patients with persistently elevated alanine amino transferase (ALT) levels (>60 IU/l), detectable HCV RNA or HBV DNA in serum, and a liver biopsy that indicates either portal or bridging fibrosis or at least moderate degree of inflammation and necrosis were included under HCV or HBV related chronic hepatitis categories9. Patients with autoimmune liver disease, drug-induced hepatitis and alcoholic liver injury were excluded. Details of the study were explained to all eligible participants and informed consent was obtained. A group of 27 patients (chronic non-B, non-C hepatitis) was seronegative for both HBV and HCV markers as revealed by ELISA and PCR studies. History of blood transfusion (HBT) was recorded in 8 patients in this group. Another group of 23 patients (chronic hepatitis B) was seropositive for HBsAg and HBV DNA and seronegative for anti-HCV and HCV RNA. Six patients had HBT in this group. A total of 20 patients (chronic hepatitis C) were seropositive for anti-HCV and HCV RNA and seronegative for HBsAg and HBV DNA. Eleven patients in this group had HBT. The healthy controls (n=100) were drawn from healthy men and women voluntary blood donors with normal liver function test (LFT) profiles and serologically negative for HBV and HCV. Twenty individuals had HBT in this group. The TTV positivity in controls was found to be 52 per cent in another study10. Allowing a difference of 20% ± 10 it was found that at 95 per cent confidence limit 96 samples would be needed for the study. We therefore, included 100 controls in this study.

Serology: Serum samples collected from all 70 chronic hepatitis patients and 100 healthy control subjects were included for serological tests for hepatitis B and C viruses viz., HBsAg using Eliscaan micro ELISA strips (Ranbaxy Diagnostics, England), Anti-HCV by Innotest HCV AB III (Innogenetics NV, Ghent, Belgium).

Detection of TTV DNA: Total DNA from 100 µl serum was extracted by standard proteinase-K/phenol/chloroform method and was subjected to PCR8. TTV DNA was detected in serum by nested PCR using the primers described by Tanaka et al11 that belonged to UTR (A) region of the genome. Briefly, DNA was amplified by PCR with 0.75 Units of Taq DNA polymerase (Bangalore Genei, India) for 35 cycles at 94°C for 30 sec, 55°C for 30 sec and 72°C for 45 sec, followed by 7 min extension at 72°C after the last cycle, in a 100-PTC thermal cycler (MJ Research, USA).

The final PCR product of 110 base pairs was visualized with UV-Transilluminator (Vilber Lourmat, France) after electrophoresis on a 2 per cent agarose gel stained with ethidium bromide.

Statistical test: The statistical tests included analysis of variance (ANOVA), Bon-ferroni test of multiple comparisons, Chi-square/Fisher exact test and student t-test wherever applicable. P values less than 0.05 were taken as statistically significant.

Results & Discussion

Presence of TTV DNA in chronic hepatitis patients and healthy controls: TTV DNA was detected in 9 of 70 patients (12.8%) with chronic hepatitis, which was not significantly different from the controls (12 of 100, 12%). TTV positivity in patients with hepatitis B (26%) was significantly higher (P

Clinical differences between the TTV-positive and TTV-negative groups with chronic hepatitis: The age distribution between TTV-positive and TTV-negative patients did not differ significantly (Table II). The proportion of patients with blood transfusion histories was higher in the TTV-positive group than in TTV-negative group. The sex distribution was not significantly different between TTV-positive and TTV-negative groups. Also, mean ALT levels between TTV-positive and TTV-negative groups did not differ significantly (Table II).

In the present study, the prevalence of TTV in patients with chronic liver diseases (12.8%) was found to be similar to that in healthy blood donors (12%). Arankalle et al1 reported TTV positivity only in HBV DNA positive subset of chronic hepatitis patients. However, detailed clinical data of the patients like age, sex, history of blood transfusions were not studied. Several studies have revealed high (1.9 to 36%) TTV DNA prevalence in healthy control groups6,12-18. Interestingly, in the present study TTV when present in chronic hepatitis patients was always associated with either HBV or HCV. Also, the presence of TTV infection in our study population had no significant impact on the clinical implications of patients with chronic hepatitis. Thus, the clinical significance of TTV could not be ascertained in chronic hepatitis cases.

In conclusion, our study did not indicate TTV as a causative agent of non-B, non-C chronic hepatitis cases studied at our centre and TTV might be an innocent bystander, which is unlikely to influence the course of the disease.

Acknowledgment

Authors acknowledge partial financial support from University Grants Commission, New Delhi, and thank Dr A. Sehgal, Ms. Shashi and Ms. Sarita, Institute of Cytology and Preventive Oncology (ICPO), Noida, for the statistical analysis of data.

References

1. Arankalle VA, Gandhe SS, Deshmukh TM, Chadha MS, Walimbe AM. Prevalence and phylogenetic analysis of TT virus DNA in western India. Clin Diagn Lab Immunol 2000; 7 : 845-9.

2. Charlton M, Adjei P, Poterucha J, Zein N, Moore B, Therneau T, et al. TT-virus infection in North American blood donors, patients with fulminant hepatic failure, and cryptogenic cirrhosis. Hepatology 1998; 28 : 839-42.

3. Desai SM, Muerhoff AS, Leary TP, Erker JC, Simons JN, Chalmers ML, et al. Prevalence of TT virus infection in US blood donors and populations at risk for acquiring parenterally transmitted viruses. J Infect Dis 1999; 179 : 1242-4.

4. Ikeuchi T, Yokosuka O, Kanda T, Imazeki F, Seta T, Saisho H. Roles of TT virus infection in various types of chronic hepatitis. Intervirology 2001; 44 : 219-23.

5. Lin CL, Kyono W, Tongson J, Chua PK, Easa D, Yanagihara R, et al. Fecal excretion of a novel human circovirus, TT virus, in healthy children. Clin Diagn Lab Immunol 2000; 7 : 960-3.

6. Naoumov NV, Petrova EP, Thomas MG, Williams R. Presence of a newly described human DNA virus (TTV) in patients with liver disease. Lancet 1998; 352 : 195-7.

7. Alter HJ, Nakatsuji Y, Melpolder J, Wages J, Wesley R, Shih JW, et al. The incidence of transfusion associated hepatitis G virus infection and its relation to liver disease. N Engl J Med 1997; 336 : 747-54.

8. Mushahwar, IK, Erker JC, Muerhoff AS, Leary TP, Simons JN, Birkeanmeyer LG, et al. Molecular and biophysical characterization of TT virus: evidence for a new virus family infecting humans. Proc Natl Acad Sci USA 1999; 96 : 3177-82.

9. Ishak K, Babtista A, Bianchi L, Callea F, De Groote J, Gudat F. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22 : 696-9.

10. Das K, Kar P, Gupta RK, Das BC. Role of transfusion-transmitted virus in acute viral hepatitis and fulminant hepatic failure of unknown etiology. J Gastroenterol Hepatol 2004; 19 : 406-12.

11. Tanaka H, Okamoto H, Luengrojanakul P, Chainuvati T, Tsuda F, Tanaka T, et al. Infection with an unenveloped DNA virus (TTV) associated with post-transfusion non-A to G hepatitis in hepatitis patients and healthy blood donors in Thailand. J Med Virol 1998; 56 : 234-8.

12. Ikeda H, Takasu M, Inoue K, Okamoto H, Miyakawa Y, Mayumi M. Infection with an unenveloped DNA virus (TTV) in patients with acute or chronic liver disease of unknown etiology and in those positive for hepatitis C virus RNA. J Hepatol 1999; 30 : 205-12.

13. Yzebe D, Xueref S, Baratin D, Bouletreau A. Fabry J, Vanhems P. TT virus. A review of the literature. Panminerva Med 2002; 44 : 167-77.

14. Zein NN. TT virus infection: an emerging pathogen in search of its identity. J Pediatr 2000; 136 : 573-5.

15. Saback FL, Gomes SA, de Paula VS, da Silva RR, Lewis-Ximenez LL, Niel C. Age-specific prevalence and transmission of TT virus. J Med Virol 1999; 59 : 318-22.

16. Nishizawa T, Okamoto H, Konishi K, Yoshizawa H, Miyakawa Y. Mayumi M. A novel DNA virus (TTV) associated with elevated transaminase levels in post-transfusion hepatitis of unknown etiology. Biochem Biophys Res Commun 1997; 241 : 92-7.

17. Okamoto H, Nishizawa T, Kato N, Ukita M, Ikeda H, Iizuka H, et al. Molecular cloning and characterization of a novel DNA virus (TTV) associated with post-transfusion hepatitis of unknown etiology. Hepatol Res 1998; 10 : 1-16.

18. Prescott LE, Simmonds P. Global distribution of transfusion-transmitted virus. N Engl J Med 1998; 339 : 776-7.

Saket Chattopadhyay, B.C. Das*, R.K. Gupta & P. Kar

PCR-Hepatitis Laboratory, Department of Medicine, Maulana Azad Medical College, New Delhi & * Institute of Cytology & Preventive Oncology (ICMR), Noida, India

Received April 18, 2004

Reprint requests: Dr P. Kar, D-II/M-2755, Netaji Nagar, New Delhi 110023, India

e-mail: pkar@vsnl.com

Copyright Indian Council of Medical Research Jul 2005
Provided by ProQuest Information and Learning Company. All rights Reserved

Return to Alcoholic hepatitis
Home Contact Resources Exchange Links ebay